Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
The University of Texas MD Anderson Cancer Center · Dana-Farber/Boston Children's Cancer and Blood Disorders Center · +35 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
987
total citations
- FWCI
- 77.38
- Percentile
- 100%
- References
- 25
Citations per year
Authors
29- DSDavid S. Hong
The University of Texas MD Anderson Cancer Center
- SGSteven G. DuBois
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard University
- SKShivaani Kummar
Stanford University
- AFAnna F. Farago
Massachusetts General Hospital
- CMCatherine M. Albert
Seattle Children's Hospital, University of Washington
Topics & keywords
Topics
Keywords
- Trk receptor
- Medicine
- Internal medicine
- Pooled analysis
- Population
- Clinical endpoint
- Clinical trial
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.